OUR EXPERTISE<\/h6>\nA know-how and competencies<\/h2><\/h1><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>As an independent pharmaceutical company, our strategy is mainly based on mature products with high medical values.<\/p>\n
Our expertise is used to acquire and maintain products that have stood the test of time while continuing to meet an important medical need.<\/p>\n
With the benefit of their extensive experience in the pharmaceutical industry, Delbert Pharma has built a multidisciplinary team eager to put their skills at the service of patients. Experts in the health field, Delbert Pharma has an expertise in regulatory affairs, quality assurance as well as in the scientific, medical and legal fields.<\/p>\n<\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>History of an independent French laboratory<\/h3><\/h2><\/div>2002<\/h4><\/a><\/li>
2012<\/h4><\/a><\/li>
2013<\/h4><\/a><\/li>
2014<\/h4><\/a><\/li>
2016<\/h4><\/a><\/li>
2017<\/h4><\/a><\/li>
2018<\/h4><\/a><\/li>
2019<\/h4><\/a><\/li>
2024 <\/h4><\/a><\/li><\/ul><\/div>2002<\/h4><\/a><\/li><\/ul><\/div>\n![\"lancement](\"https:\/\/staging24.delbertpharma.com\/wp-content\/uploads\/2020\/03\/construction-start-up-1-300x215.gif\")
\n2002 –\u00a0 CREATION OF LABORATOIRES DELBERT by Michel BERTHIER, pharmacist.<\/h6>\n
Experts in regulatory affairs, Michel Berthier and his daughter Laurence Delemotte, created Laboratoires DELBERT. The two pharmacists offer a service of regulatory activities: more than 300 Marketing Authorization files for generic drugs were registered in 10 years<\/p>\n<\/div>
2012<\/h4><\/a><\/li><\/ul><\/div>\n![\"bi-citrol\"](\"https:\/\/staging24.delbertpharma.com\/wp-content\/uploads\/2020\/03\/bi-citrol-300x300.jpg\")
\n2012 –\u00a0 LABORATOIRES DELBERT, A PHARMACEUTICAL COMPANY<\/h6>\n
Laboratoires DELBERT acquire their first pharmaceutical specialty: Bi-citrol\u00ae and become a pharmaceutical company with an “exploitant” status.<\/p>\n<\/div>
2013<\/h4><\/a><\/li><\/ul><\/div>\n![\"hommes](\"https:\/\/staging24.delbertpharma.com\/wp-content\/uploads\/2020\/03\/Delbert-hommes-mains.jpeg\")
<\/h6>\n<\/h6>\n2013 –\u00a0BIRTH OF A START UP<\/h6>\n
Laboratoires DELBERT are bought by Thierry HOFFMANN, industrial pharmacist and Marc CHILDS, psychiatrist.<\/p>\n<\/div>
2014<\/h4><\/a><\/li><\/ul><\/div>\n![\"\"](\")
<\/p>\n
<\/h6>\n2014 – CREATING A MODEL<\/h6>\n
Acquisition and return to the market of Vercyte\u00ae (Pipobroman).<\/p>\n
In a context of shortage of Vercyte\u00ae specialty (Pipobroman), Laboratoires DELBERT acquired the product. They register a new supplier of active ingredients and find a production site for the finished product capable of handling highly toxic substances.<\/p>\n<\/div>
2016<\/h4><\/a><\/li><\/ul><\/div>\n![\"\"](\"https:\/\/staging24.delbertpharma.com\/wp-content\/uploads\/2021\/12\/PIPORTIL-100MG_ML_1AMP_Palmitate-de-pipotiazine_laboratoires_delbert.png\")
<\/h6>\n
2016 –\u00a0EXPANSION OF PRODUCT’S PORTFOLIO<\/p>\n
Acquisition of the Piportil \u00ae <\/sup> \/ Piportil \u00ae <\/sup> L4 (Pipotiazine) range<\/p>\nThreatened with marketing discontinuation, Laboratoires DELBERT commit to maintaining PIPORTIL and PIPORTIL L4 in the psychiatric therapeutic arsenal.<\/p>\n<\/div>
2017<\/h4><\/a><\/li><\/ul><\/div>\n![\"Extencilline\"](\"https:\/\/staging24.delbertpharma.com\/wp-content\/uploads\/2020\/03\/Extencilline-range-scaled-e1584988647760-300x282.jpg\")
\n2017 – REDEVELOP EUROPEAN KNOW-HOW<\/h6>\n
Returned to the market of Extencilline\u00ae (Benzathine benzylp\u00e9nicilline)<\/p>\n
Laboratoires DELBERT identify a European production site with an infrastructure suitable for the fermentation of penicillin. Reactivation of the production site allows benzathine benzylpenicillin-based medicine to be made available on the market again.<\/p>\n<\/div>
A know-how and competencies<\/h2><\/h1><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>As an independent pharmaceutical company, our strategy is mainly based on mature products with high medical values.<\/p>\n
Our expertise is used to acquire and maintain products that have stood the test of time while continuing to meet an important medical need.<\/p>\n
With the benefit of their extensive experience in the pharmaceutical industry, Delbert Pharma has built a multidisciplinary team eager to put their skills at the service of patients. Experts in the health field, Delbert Pharma has an expertise in regulatory affairs, quality assurance as well as in the scientific, medical and legal fields.<\/p>\n<\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>History of an independent French laboratory<\/h3><\/h2><\/div>2002<\/h4><\/a><\/li>
2012<\/h4><\/a><\/li>
2013<\/h4><\/a><\/li>
2014<\/h4><\/a><\/li>
2016<\/h4><\/a><\/li>
2017<\/h4><\/a><\/li>
2018<\/h4><\/a><\/li>
2019<\/h4><\/a><\/li>
2024 <\/h4><\/a><\/li><\/ul><\/div>2002<\/h4><\/a><\/li><\/ul><\/div>\n
\n2002 –\u00a0 CREATION OF LABORATOIRES DELBERT by Michel BERTHIER, pharmacist.<\/h6>\n
Experts in regulatory affairs, Michel Berthier and his daughter Laurence Delemotte, created Laboratoires DELBERT. The two pharmacists offer a service of regulatory activities: more than 300 Marketing Authorization files for generic drugs were registered in 10 years<\/p>\n<\/div>
2012<\/h4><\/a><\/li><\/ul><\/div>\n
\n2012 –\u00a0 LABORATOIRES DELBERT, A PHARMACEUTICAL COMPANY<\/h6>\n
Laboratoires DELBERT acquire their first pharmaceutical specialty: Bi-citrol\u00ae and become a pharmaceutical company with an “exploitant” status.<\/p>\n<\/div>
2013<\/h4><\/a><\/li><\/ul><\/div>\n<\/h6>\n<\/h6>\n2013 –\u00a0BIRTH OF A START UP<\/h6>\n
Laboratoires DELBERT are bought by Thierry HOFFMANN, industrial pharmacist and Marc CHILDS, psychiatrist.<\/p>\n<\/div>
2014<\/h4><\/a><\/li><\/ul><\/div>\n<\/p>\n
<\/h6>\n2014 – CREATING A MODEL<\/h6>\n
Acquisition and return to the market of Vercyte\u00ae (Pipobroman).<\/p>\n
In a context of shortage of Vercyte\u00ae specialty (Pipobroman), Laboratoires DELBERT acquired the product. They register a new supplier of active ingredients and find a production site for the finished product capable of handling highly toxic substances.<\/p>\n<\/div>
2016<\/h4><\/a><\/li><\/ul><\/div>\n<\/h6>\n
2016 –\u00a0EXPANSION OF PRODUCT’S PORTFOLIO<\/p>\n
Acquisition of the Piportil \u00ae <\/sup> \/ Piportil \u00ae <\/sup> L4 (Pipotiazine) range<\/p>\nThreatened with marketing discontinuation, Laboratoires DELBERT commit to maintaining PIPORTIL and PIPORTIL L4 in the psychiatric therapeutic arsenal.<\/p>\n<\/div>
2017<\/h4><\/a><\/li><\/ul><\/div>\n
\n2017 – REDEVELOP EUROPEAN KNOW-HOW<\/h6>\n
Returned to the market of Extencilline\u00ae (Benzathine benzylp\u00e9nicilline)<\/p>\n
Laboratoires DELBERT identify a European production site with an infrastructure suitable for the fermentation of penicillin. Reactivation of the production site allows benzathine benzylpenicillin-based medicine to be made available on the market again.<\/p>\n<\/div>
As an independent pharmaceutical company, our strategy is mainly based on mature products with high medical values.<\/p>\n
Our expertise is used to acquire and maintain products that have stood the test of time while continuing to meet an important medical need.<\/p>\n
With the benefit of their extensive experience in the pharmaceutical industry, Delbert Pharma has built a multidisciplinary team eager to put their skills at the service of patients. Experts in the health field, Delbert Pharma has an expertise in regulatory affairs, quality assurance as well as in the scientific, medical and legal fields.<\/p>\n<\/div>
History of an independent French laboratory<\/h3><\/h2><\/div>2002<\/h4><\/a><\/li>
2012<\/h4><\/a><\/li>
2013<\/h4><\/a><\/li>
2014<\/h4><\/a><\/li>
2016<\/h4><\/a><\/li>
2017<\/h4><\/a><\/li>
2018<\/h4><\/a><\/li>
2019<\/h4><\/a><\/li>
2024 <\/h4><\/a><\/li><\/ul><\/div>2002<\/h4><\/a><\/li><\/ul><\/div>\n
\n2002 –\u00a0 CREATION OF LABORATOIRES DELBERT by Michel BERTHIER, pharmacist.<\/h6>\n
Experts in regulatory affairs, Michel Berthier and his daughter Laurence Delemotte, created Laboratoires DELBERT. The two pharmacists offer a service of regulatory activities: more than 300 Marketing Authorization files for generic drugs were registered in 10 years<\/p>\n<\/div>
2012<\/h4><\/a><\/li><\/ul><\/div>\n
\n2012 –\u00a0 LABORATOIRES DELBERT, A PHARMACEUTICAL COMPANY<\/h6>\n
Laboratoires DELBERT acquire their first pharmaceutical specialty: Bi-citrol\u00ae and become a pharmaceutical company with an “exploitant” status.<\/p>\n<\/div>
2013<\/h4><\/a><\/li><\/ul><\/div>\n<\/h6>\n<\/h6>\n2013 –\u00a0BIRTH OF A START UP<\/h6>\n
Laboratoires DELBERT are bought by Thierry HOFFMANN, industrial pharmacist and Marc CHILDS, psychiatrist.<\/p>\n<\/div>
2014<\/h4><\/a><\/li><\/ul><\/div>\n<\/p>\n
<\/h6>\n2014 – CREATING A MODEL<\/h6>\n
Acquisition and return to the market of Vercyte\u00ae (Pipobroman).<\/p>\n
In a context of shortage of Vercyte\u00ae specialty (Pipobroman), Laboratoires DELBERT acquired the product. They register a new supplier of active ingredients and find a production site for the finished product capable of handling highly toxic substances.<\/p>\n<\/div>
2016<\/h4><\/a><\/li><\/ul><\/div>\n<\/h6>\n
2016 –\u00a0EXPANSION OF PRODUCT’S PORTFOLIO<\/p>\n
Acquisition of the Piportil \u00ae <\/sup> \/ Piportil \u00ae <\/sup> L4 (Pipotiazine) range<\/p>\nThreatened with marketing discontinuation, Laboratoires DELBERT commit to maintaining PIPORTIL and PIPORTIL L4 in the psychiatric therapeutic arsenal.<\/p>\n<\/div>
2017<\/h4><\/a><\/li><\/ul><\/div>\n
\n2017 – REDEVELOP EUROPEAN KNOW-HOW<\/h6>\n
Returned to the market of Extencilline\u00ae (Benzathine benzylp\u00e9nicilline)<\/p>\n
Laboratoires DELBERT identify a European production site with an infrastructure suitable for the fermentation of penicillin. Reactivation of the production site allows benzathine benzylpenicillin-based medicine to be made available on the market again.<\/p>\n<\/div>
2002<\/h4><\/a><\/li>
2012<\/h4><\/a><\/li>
2013<\/h4><\/a><\/li>
2014<\/h4><\/a><\/li>
2016<\/h4><\/a><\/li>
2017<\/h4><\/a><\/li>
2018<\/h4><\/a><\/li>
2019<\/h4><\/a><\/li>
2024 <\/h4><\/a><\/li><\/ul><\/div>
2002<\/h4><\/a><\/li><\/ul><\/div>
\n
\n2002 –\u00a0 CREATION OF LABORATOIRES DELBERT by Michel BERTHIER, pharmacist.<\/h6>\nExperts in regulatory affairs, Michel Berthier and his daughter Laurence Delemotte, created Laboratoires DELBERT. The two pharmacists offer a service of regulatory activities: more than 300 Marketing Authorization files for generic drugs were registered in 10 years<\/p>\n<\/div>
2012<\/h4><\/a><\/li><\/ul><\/div>
\n
\n2012 –\u00a0 LABORATOIRES DELBERT, A PHARMACEUTICAL COMPANY<\/h6>\nLaboratoires DELBERT acquire their first pharmaceutical specialty: Bi-citrol\u00ae and become a pharmaceutical company with an “exploitant” status.<\/p>\n<\/div>
2013<\/h4><\/a><\/li><\/ul><\/div>
\n<\/h6>\n<\/h6>\n
2013 –\u00a0BIRTH OF A START UP<\/h6>\n
Laboratoires DELBERT are bought by Thierry HOFFMANN, industrial pharmacist and Marc CHILDS, psychiatrist.<\/p>\n<\/div>
2014<\/h4><\/a><\/li><\/ul><\/div>
\n<\/h6>\n
2014 – CREATING A MODEL<\/h6>\n
Acquisition and return to the market of Vercyte\u00ae (Pipobroman).<\/p>\n
In a context of shortage of Vercyte\u00ae specialty (Pipobroman), Laboratoires DELBERT acquired the product. They register a new supplier of active ingredients and find a production site for the finished product capable of handling highly toxic substances.<\/p>\n<\/div>
2016<\/h4><\/a><\/li><\/ul><\/div>
\n<\/h6>\n2016 –\u00a0EXPANSION OF PRODUCT’S PORTFOLIO<\/p>\n
Acquisition of the Piportil \u00ae <\/sup> \/ Piportil \u00ae <\/sup> L4 (Pipotiazine) range<\/p>\n
Threatened with marketing discontinuation, Laboratoires DELBERT commit to maintaining PIPORTIL and PIPORTIL L4 in the psychiatric therapeutic arsenal.<\/p>\n<\/div>
2017<\/h4><\/a><\/li><\/ul><\/div>
\n
\n2017 – REDEVELOP EUROPEAN KNOW-HOW<\/h6>\nReturned to the market of Extencilline\u00ae (Benzathine benzylp\u00e9nicilline)<\/p>\n
Laboratoires DELBERT identify a European production site with an infrastructure suitable for the fermentation of penicillin. Reactivation of the production site allows benzathine benzylpenicillin-based medicine to be made available on the market again.<\/p>\n<\/div>
![\"Bristopen\"](\"https:\/\/staging24.delbertpharma.com\/wp-content\/uploads\/2020\/03\/Istopen-scaled-e1584988179856-300x300.jpg\")
![\"Oxycodone\"](\"https:\/\/staging24.delbertpharma.com\/wp-content\/uploads\/2020\/03\/Oxycodone-Range-scaled-e1584988287824-300x250.jpg\")